A share price of Protagonist Therapeutics Inc [PTGX] is currently trading at $59.22, up 1.08%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PTGX shares have gain 2.56% over the last week, with a monthly amount glided 5.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $72. Previously, Leerink Partners started tracking the stock with Outperform rating on September 12, 2025, and set its price target to $73. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $72 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $47 on December 06, 2024. BMO Capital Markets initiated its recommendation with a Outperform and recommended $62 as its price target on December 06, 2024. Wedbush started tracking with a Outperform rating for this stock on November 05, 2024, and assigned it a price target of $58. In a note dated September 24, 2024, TD Cowen initiated an Buy rating and provided a target price of $65 on this stock.
Protagonist Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $33.31 and $61.89. Currently, Wall Street analysts expect the stock to reach $66.2 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $59.22 at the most recent close of the market. An investor can expect a potential return of 11.79% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Trailing Twelve Months sales for Protagonist Therapeutics Inc [NASDAQ:PTGX] were 209.18M which represents 33.09% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.08 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Protagonist Therapeutics Inc [NASDAQ:PTGX] is 16.97. In addition, the Quick Ratio stands at 16.97 and the Cash Ratio stands at 4.75. Considering the valuation of this stock, the price to sales ratio is 17.61, the price to book ratio is 5.51 and price to earnings (TTM) ratio is 83.10.
Transactions by insiders
Recent insider trading involved Waddill William D., Director, that happened on Aug 27 ’25 when 4000.0 shares were sold. Director, WILLIAM WADDILL completed a deal on Aug 27 ’25 to buy 4000.0 shares. Meanwhile, President and CEO PATEL DINESH V PH D sold 10415.0 shares on Jul 25 ’25.
